Rapid Communications |
-Tropomyosin Ablation in the Mouse
From the Department of Molecular Genetics, Biochemistry, and Microbiology (P.R., D.F.W.) and the Department of Pathology and Laboratory Medicine (G.B.), University of Cincinnati (Ohio) Medical Center; the Department of Medical Physiology (M.M.), Texas A&M University Health Science Center, College Station; the Division of Molecular Cardiovascular Biology (T.H.), Children's Hospital Medical Center, Cincinnati, Ohio; and the Department of Physiology and Biophysics (B.M.W., C.E., R.J.S.), University of Illinois at Chicago.
Correspondence to Dr David F. Wieczorek, Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati Medical Center, Cincinnati, OH 45267-0524. E-mail wieczodf{at}ucbeh.san.uc.edu
| Abstract |
|---|
|
|
|---|
-TM, the murine
-TM gene was disrupted by homologous recombination. Homozygous
-TM null mice are embryonic lethal, dying between 8 and 11.5 days
post coitum. Mice that are heterozygous for
-TM are viable and
reproduce normally. Heterozygous knockout mouse hearts show a 50%
reduction in cardiac muscle
-TM mRNA, with no compensatory increase
in transcript levels by striated muscle ß-TM or TM-30 isoforms.
Surprisingly, this reduction in
-TM mRNA levels in heterozygous mice
is not reflected at the protein level, where normal amounts of striated
muscle
-TM protein are produced and integrated in the myofibril.
Quantification of
-TM mRNA bound in polysomal fractions reveals that
both wild-type and heterozygous knockout animals have similar levels.
These data suggest that a change in steady-state level of
-TM mRNA
does not affect the relative amount of mRNA translated and amount of
protein synthesized. Physiological analyses
of myocardial and myofilament function show no differences between
heterozygous
-TM mice and control mice. The present study
suggests that translational regulation plays a major role in the
control of TM expression.
Key Words: tropomyosin knockout mouse translational regulation
| Introduction |
|---|
|
|
|---|
-helical
coiled-coil dimer, with each molecule interacting with six or seven
actin monomers. The TMs bind to themselves in a head-to-tail manner and
wrap around the actin molecule to stabilize thin filament assembly.
Although the exact role of TM is still not completely understood, the
TM-troponin complex inhibits the actin-myosin interaction in the
resting state; with an increase of Ca2+ in the
myofilament space and binding of Ca2+ to
troponin, this inhibition is released and leads to muscle
contraction.
TM is encoded by a small multigene family consisting of the
, ß,
TM-30, and TM-4 genes. These genes, and associated proteins, exhibit a
very high degree of conservation across species ranging from
Drosophila to humans. For example, there is 86% amino acid
conservation between the striated muscle
- and ß-TM
isoforms.1 Previous work conducted by our
laboratory2 3 and others4 5
has demonstrated that TM isoforms are generated through alternative
exon splicing and are regulated in a developmental and tissue-specific
manner. The functional significance of the alternatively spliced TM
domains and the physiological role of the TM
isoforms produced by the various multigene family members remain to be
determined.
During murine cardiac development,
- and ß-TMs are expressed at
different levels.3 6 During fetal development,
-TM represents 80% of the total TM in the heart, and 20%
is ß-TM. In the adult heart, ß-TM represents 2% of TM
expression, with
-TM representing
98%.3 However, during pressure-overload
hypertrophy, ß-TM is reexpressed in the
heart.7 The long-term goal of our laboratory is
to understand the role of different TM isoforms in muscle contraction.
We have chosen a transgenic mouse approach to address this research
area. We recently created a transgenic mouse model that overexpresses
ß-TM specifically in the heart. These studies show that an increased
overexpression of ß-TM results in hearts that contain 45%
-TM and
55% ß-TM in their myofibrils; however, there is no change in the
total amount of TM protein (
+ß-TM) that is produced in these
transgenic mouse hearts.6
Physiological analyses using a
work-performing heart model reveal that diastolic function
is significantly altered in these mice by a decreased rate of
relaxation, coupled with a delay in the time of relaxation. A possible
explanation for this altered diastolic function is that the
cardiac myofilaments demonstrate an increase in
Ca2+ sensitivity of steady-state
force.8
In the present study, we have addressed whether underexpression of
-TM mRNA would alter
-TM protein levels and cardiac function. To
underexpress
-TM transcripts, we ablated the
-TM striated
musclespecific exons in murine ES cells by homologous recombination
and substitution with an HPRT minigene cassette. Results
from heterozygous (+/-) knockout mice show there is a 50% reduction
in
-TM mRNA in the targeted mouse hearts. There is no compensation
at the transcript level for decreased
-TM expression by either
ß-TM or the slow-twitch
-TM isoform (TM-30). Interestingly, the
-TM protein level in cardiac myofibrils is not reduced in the
heterozygous mutant mice, nor are there functional differences in
cardiac performance. Results suggest that normal protein levels
are maintained in these heterozygous mice through an increased
translatability of
-TM transcripts.
| Materials and Methods |
|---|
|
|
|---|
-TMstr Targeting Construct
-TM
genomic fragment containing the striated musclespecific exons 12 and
13 with a 2.9-kb HPRT minigene cassette cloned in reverse
orientation to the
-TM transcription (Fig 1
-TMstr or (2) complete ablation of all
-TM transcripts. A
2-kb herpes simplex virusthymidine kinase cassette used as a negative
selection marker was cloned downstream from the long homology arm. The
13.6-kb construct was linearized by NotI endonuclease
digestion for ES cell electroporation.
|
Generation of
-TMstr Mutant Mice
Five nanomoles of the linearized construct was
electroporated into 2x107
E14TG2a(HPRT-) cells. The ES cells
were subsequently cultured in the presence of HAT (120 µmol/L
hypoxanthine/0.4 µmol/L aminopterin/20 µmol/L thymidine)
and ganciclovir (Sigma Chemical Co). Among the 153 positive ES cell
clones, homologous recombination was confirmed in 22 ES cell colonies
by Southern blot analysis. Three different ES cell clones were
selected for blastocyst injection, and successful germ-line
transmission was confirmed in one line; chimeric males were bred to
Black Swiss females to establish the colony.
Southern Blot Analysis
Genomic DNA from tails and embryos was extracted by overnight
lysis at 60°C. Ten micrograms of the genomic DNA was restricted,
Southern-blotted, and hybridized with
32P-radiolabeled
-TM probes. The 5' probe
consists of the XbaI-SphI fragment surrounding
exon 7, and the 3' probe consists of the
XhoI-EcoRI fragment located downstream from exon
13. The blots were washed with 0.5x SSC and 0.1% SDS at 65°C and
exposed to Kodak x-ray film.
S1 Nuclease Mapping Analysis
Total RNA was isolated from hearts and skeletal muscle of
wild-type and heterozygous mice and subjected to S1 nuclease mapping
analysis as described.2 6 Twenty
micrograms of total RNA was hybridized to single-stranded TM and GAPDH
DNA probes (4x104 cpm). The murine GAPDH probe
was used as an internal control for the reactions and levels of
transcripts. Both TM and GAPDH probes were in DNA excess and were
subject to S1 analyses in the same reaction tube. The protected
fragments were quantified by comparison of the intensities of the TM
fragments with the corresponding GAPDH fragment using a PhosphorImager
(Molecular Dynamics).
Western Blot Analysis
Total extract and myofibrillar protein fractions were prepared
from hearts of wild-type and heterozygous mice as
described.9 Predetermined concentrations of
myofibrillar protein was electrophoresed on 10%
SDS-polyacrylamide gels and either stained with Coomassie blue
or transferred to nitrocellulose membrane for Western blotting with a
monoclonal TM antibody (Sigma).
Quantification of
-TM mRNA Bound to Polysomes
The polysome profile analysis was performed according to
established procedures.10 Wild-type and
heterozygous hearts were homogenized in 10 mmol/L
Tris-HCl (pH 7.4), 100 mmol/L KCl, 10 mmol/L
MgCl2, and 1 mmol/L dithiothreitol. The
homogenate was centrifuged at 13 000g
for 30 minutes to remove the mitochondria. Ten absorbance units
(OD260) of the postmitochondrial supernatant were
layered onto 12.5 mL of 10% to 45% (wt/vol) sucrose density gradient
in the above buffer prepared in a Bio-Rad density gradient maker. The
gradients were centrifuged in a Beckman SW40 Ti rotor at
38 000 rpm for 100 minutes at 4°C. Fractions (0.5 mL) were collected
by upward displacement, and the OD254 was
measured and plotted. RNA isolated from the fractions was slot-blotted
onto nitrocellulose membrane and hybridized with random primerlabeled
([32P]dCTP)
-TMstr cDNA probe and washed
under stringent conditions.
Physiological Analyses
A functional analysis of the heart was
ascertained by using the work-performing heart model. The working heart
preparations were performed as described
previously.11 12 Seven wild-type and six
heterozygous
-TM knockout mice were age- and sex-matched for the
analysis. To compare to what extent the hearts could be loaded,
cardiac work was varied from 100 to 600 mm HgxmL/min. Mean±SE
values were calculated for heart rate,
intraventricular pressure, and rates of contraction
and relaxation.
Force measurements in bundles of detergent-extracted fibers were
measured by a modification of previously described
methods.8 Adult mice were anesthetized
with pentobarbital sodium (50 mg/kg body wt IP), and hearts were
quickly removed and put into cold HR solution of the following
composition (mmol/L): EGTA 10, MOPS 20, free Mg2+
1, MgATP2- 5, and creatine phosphate 12, along
with 10 IU/mL creatine phosphokinase. The pH of the solution was
adjusted to 7.0 with KOH. The ionic strength of all solutions was
150 mmol/L. The papillary muscles from the left ventricle were
dissected, and small fiber bundles
150 to 20 µm in width and
4 to 5 mm long were prepared. Fiber bundles were mounted between a
micromanipulator and a force transducer with cellulose-acetate glue.
Fibers were skinned in the HR solution containing 1% Triton X-100 for
30 minutes. A sarcomere length of 2.0 µm was established from
laser diffraction patterns. Isometric tension was recorded on a
chart recorder. After they were skinned, the fibers were initially
washed in HR solution and then sequentially bathed in LR solution,
followed by solutions of varying pCa values (pCa range, from 8.0 to
4.5). The ionic composition of all solutions was computed using a
computer program. Compared with HR solution, LR solution contained
0.1 mmol/L EGTA. All solutions also contained the protease
inhibitors pepstatin A (2.5 µg/mL), leupeptin (1
µg/mL), and phenylmethylsulfonyl fluoride (50
µmol/L).
| Results |
|---|
|
|
|---|
-TM Genomic Locus
-TM gene, we have isolated the murine TM locus,
which spans 24 kb of DNA and contains several alternatively spliced
exons (Fig 1
-TM striated muscle isoformspecific
knockout or a complete ablation of the
-TM gene. Fig 1
-TM locus, the gene-targeting construct, and the targeted
allele after homologous recombination and insertion of the
HPRT minigene into the
-TM locus. The HPRT
minigene cassette was cloned in reverse orientation to the
-TM
transcription unit; a tk cassette was inserted at the end of the
targeting construct to allow for negative selection.
To obtain targeted ES cells, the linearized
-TMstr construct
was electroporated into
E14TG2a(HPRT-) ES cells. With HAT
media used as a positive selection system and ganciclovir as a negative
selection agent, 153 ES cell clones were selected. Genomic Southern
blot analyses of DNA from ES cell clones were performed to
detect the targeting event. The 5' probe consisted of the
XbaI-SphI fragment surrounding exon 7, and the 3'
probe was the XhoI-EcoRI fragment downstream from
exon 13. Hybridization with the 5' probe on
HindIII-XhoIdigested DNA from correctly
targeted ES cell clones detected 6-kb (wild-type allele) and 4-kb
(targeted allele) bands (Fig 2A
).
Hybridization with the 3' probe detected 9-kb (wild-type allele)
and 4.6-kb (targeted allele) bands (Fig 2A
). The correct targeting
event was confirmed in 22 clones.
|
Generation of
-TM Knockout Mice
Three correctly targeted ES cell clones were selected for
blastocyst-mediated transgenesis. All three clones produced chimeric
mice, and successful germ-line transmission was obtained in one line.
Southern blot analyses of genomic tail DNA from wild-type and
heterozygous knockout mice are shown in Fig 2B
. The probes used in
these analyses are similar to those shown in the ES cell
targeting experiment (see above).
Characterization of Transgenic Mice
Heterozygous
-TM mice were distinguished from their littermate
controls by genomic Southern blot analyses. The hearts were
obtained from heterozygous (+/-) and control mice and examined at both
the histological and morphological levels. We did not
detect any obvious differences in cardiac morphology between the two
groups (data not shown). In addition, these heterozygous mice live a
full lifespan and reproduce well.
The generations of homozygous mice through matings from heterozygous
crosses do not produce viable offspring. To determine when embryonic
and/or fetal loss was occurring, litters from timed pregnant females
were analyzed at different gestational periods. When embryos
from 8 to 11.5 days pc were isolated, there was an unusually high
number of resorptions. Embryos were individually collected (free from
contaminating maternal tissue), and genomic DNA was isolated and
examined by Southern blot analysis. Results show that the
resorbed embryos were homozygous for the targeted
-TM loci (Fig 2C
).
Thus, homozygous null embryos die in utero between day 8 to 11.5 pc,
which correlates with the time of formation of the embryonic heart
tube. These results demonstrate that
-TM protein is essential for
embryonic viability.
Determination of TM mRNA Levels in
-TM (+/-) Mice
We have previously shown that the striated muscle
-TM isoform
constitutes 98% of the total TM message in the
heart.3 6 To determine the level of
-TMstr
transcripts in heart and skeletal muscle of the
-TM heterozygous
knockout mice, we performed S1 nuclease mapping analyses. Total
RNA, isolated from hearts and skeletal muscle of both heterozygous and
wild-type mice, was hybridized with an
-TMstr cDNA probe and a GAPDH
probe (Fig 3A
). The amount of
-TMstr
message in the heterozygous striated muscle was quantified (using
PhosphorImager analyses) by comparing the densities of the
protected bands obtained with a 363-bp probe specific for
-TMstr
with a normalizing control GAPDH probe. Results from several
quantitative PhosphorImager analyses using different striated
muscle RNA samples show a 52±4.8% reduction in the
-TMstr mRNA
levels in cardiac and skeletal muscles of heterozygous mice compared
with wild-type control mice.
|
In addition to
-TM, ß-TM is expressed in the heart during murine
embryogenesis and in response to pressure-overload
hypertrophy in the adult animal.3 7
To determine whether loss of
-TM is compensated by ß-TM or by
other TM isoforms in the heterozygous knockout mice, we performed S1
nuclease mapping analyses using a ß-TM probe. Results show
that the expression of ß-TM levels in heterozygous hearts is similar
to that in wild-type hearts (Fig 3B
). These data suggest that ß-TM
does not compensate for the reduction in
-TM transcript levels.
Also, ß-TM isoform levels in skeletal muscles of both wild-type and
heterozygous mice are similar. Thus, the loss of
-TMstr message due
to targeted ablation is not compensated by a ß-TM isoform
replacement. Also, we did not observe any expression of the
-TM slow
skeletal (TM-30) isoform in these hearts (data not shown).
-TM Protein Levels Are Not Altered in the Heterozygous (+/-)
Knockout Mice
To determine whether the reduction in the mRNA has affected the
-TM protein levels, we analyzed
-TM protein levels using
myofibrillar protein preparations. Analysis of myofibrillar
protein fractions purified from total heart homogenates of
wild-type and heterozygous mice did not detect any change in
-TM
levels (Fig 4A
). Also, we did not find
any significant differences in other contractile proteins. Similarly,
results from Western blot analyses showed that
-TM protein
levels were unaltered between heterozygous and control littermates (Fig 4B
). A similar result was found when total protein
homogenates were analyzed. These data demonstrate
that despite a 50% reduction in the mRNA levels, the
-TM protein
amount was not altered. These data suggest that a compensatory
mechanism may operate at the translational level to maintain normal
amounts of
-TM production.
|
Since normal
-TM protein levels are found in heterozygous mice, we
sought to determine whether a translational mechanism was acting to
compensate for the increase protein production. We isolated
polysomal fractions prepared from heterozygous and control littermate
cardiac homogenates and analyzed the polysomal
profiles and the associated
-TM mRNA within these fractions.
Polysomal fractions from sucrose gradients were collected according to
density from both wild-type and heterozygous cardiac muscle tissue
homogenates. The absorption profile of the polysomes was
identical between the two genotypes (Fig 5A
). We quantified the abundance of
-TM transcripts in the polysomal fractions using RNA slot-blot
analysis and an
-TM striated musclespecific
oligonucleotide probe. Results show that the relative
abundance of
-TM mRNA bound to polysomes in the +/- mice is similar
to that in the control mice (Fig 5B
). These polysomal fractionation/RNA
analyses were repeated several times and produced similar
results. We conclude that despite a reduction in total
-TM mRNA
levels in heterozygous mice, the amount of polysomal bound
-TM mRNA
is comparable to that in wild-type mice, thus suggesting that there is
an increased translatability for
-TM mRNA in the heterozygous
knockout mice.
|
Physiological Analysis of
-TM
Heterozygous Mice
Despite a significant reduction in
-TM mRNA,
-TM
protein levels are normal in the heterozygous cardiac myofibers.
Nevertheless, we conducted physiological
analyses on these mice to ascertain whether cardiac
performance is altered. Using a work-performing heart model, we
measured heart rates, intraventricular pressures,
and the rates of contraction and relaxation. No significant differences
in cardiac function were found between the
-TM heterozygous and
control hearts (Fig 6A
). The mean values
for rates of contraction are 5767±279 and 6380±215 mm Hg/ms for the
control and
-TM knockout mice, respectively. The mean values for
rates of relaxation are 4362.1±221.9 and 4299.6±129.0 mm Hg/ms for
control and
-TM knockout hearts, respectively. Similarly,
measurements of heart rates (327±10 and 323±5 bpm for wild-type and
knockout mice, respectively) and intraventricular
pressure (114±4 and 113±3 mm Hg for wild-type and knockout
mice, respectively) demonstrated no significant differences between the
two groups.
|
We also directly compared Ca2+ activation of
myofilaments in skinned fiber bundles prepared from hearts of wild-type
and heterozygous
-TM knockout mice. Results presented in Fig 6B
show that heterozygous
-TM knockout and wild-type myofilaments
demonstrated the same (P
.05, two-way ANOVA)
Ca2+ dependence of force generation. The
pCa50 for the wild-type myofilaments was
5.57±0.01 with a Hill n value of 3.21±0.15. For heterozygote
-TM
myofilaments, the pCa50 was 5.56±0.01, with a
Hill n value of 3.15±0.18. On the basis of the
physiological measurements of the work-performing
heart analysis and the skinned fiber bundle preparations, we
conclude that there are no significant differences in cardiac function
between the heterozygous
-TM knockout and wild-type mice.
| Discussion |
|---|
|
|
|---|
-TM in muscle development and function. Our studies show that the
heterozygous
-TM knockout mice are healthy, with no apparent
phenotypic effects from the reduced transcript levels. Also, these
heterozygous mice exhibit normal myocardial function as measured by the
work-performing heart model and pCa-force measurements. However, the
-TM homozygous null mice do not survive, dying between day 8 to 11.5
pc, which suggests that TM protein plays an important role in embryonic
development. Also, our studies show that ablation of one
-TM
allele results in a 50% reduction in
-TM mRNA. Interestingly,
this decreased
-TM mRNA expression does not translate into a change
in the endogenous
-TM protein levels. Furthermore, the
present study demonstrates that proper levels of TM are maintained
in the heterozygous
-TM (+/-) mouse, an essential feature for
normal sarcomeric development and function.
Initial studies with the
-TM targeted ES cells demonstrated that our
targeting construct, designed to eliminate only the striated muscle
-TM isoform, disrupted production of all
-TM transcripts
from the targeted allele (data not shown). Even though the
selective removal of the striated muscle exons left the adjoining exon
splice sites and branch-point sequences intact, this targeting event
essentially disrupted the normal splicing process, resulting in loss of
total mRNA synthesis. As such, these results differ from those obtained
using a similar approach in Drosophila; in
Drosophila, disruption of indirect flight muscle exons
allows the generation of other TM isoforms from the same
gene.14 Thus, our targeting strategy to
selectively ablate only the muscle-specific
-TM mRNA had scientific
precedence but generated a complete ablation of all
-TM transcripts
from the allele.
Our studies show that the
-TM homozygous null mice die during fetal
development (8 to 11.5 days pc). In the heterozygous mutant mice, there
is no evidence of compensation by striated muscle ß-TM or the slow
skeletal
-TM (TM-30) isoforms. The ß-TM isoform, which is normally
expressed during cardiogenesis, does not increase expression after
ablation of a single
-TM locus. This is quite contrary to what has
been observed with another sarcomeric thin filament protein, cardiac
-actin, in which homozygous null mice exhibit compensation by other
actin isoforms.15 Therefore, compensatory
mechanisms that are activated may differ among various thin
filament sarcomeric proteins.
The present study has demonstrated that different regulatory
mechanisms exist among contractile protein genes for maintaining
protein levels that are necessary for sarcomeric function. Cardiac
-actin knockout mice in the heterozygous state exhibit increased
expression of various actin isoforms to compensate for reduced
expression.15 Our results show that there is a
compensatory increase in expression by neither ß-TM nor TM-30
isoforms in heterozygous
-TM knockout mice; however, there is
compensation in
-TM protein production. Also, recent work in
our laboratory has shown that despite a 150-fold overexpression of
ß-TM mRNA production in the heart, the total amount of TM
protein remains unchanged.6 Interestingly, the
increased expression of ß-TM causes the endogenous
-TM
mRNA and protein levels to compensate by decreasing their expression.
However, even with this great excess of ß-TM mRNA production,
-TM protein still constitutes almost half of the total TM in the
heart. A similar situation occurs when wild-type or mutant
-TM is
overexpressed in the heart.16 17 Thus, it appears
that wild-type
-TM mRNA is translated with significantly greater
efficiency than ß-TM or mutant
-TM transcripts. These data,
coupled with the results from the present study, strongly suggest
that translational regulatory mechanisms may play a major role in
maintaining TM protein levels in the myocyte. Furthermore, these
investigations indicate that a "cross-talk" mechanism also
participates in controlling the regulation and expression of the
different TM isoforms. Current investigations are directed toward
understanding and identifying the trans-acting factors that
control the feedback mechanism regulating TM isoform
production.
Studies of TM mutations and ablations have demonstrated the essential
function of the TM molecule. In yeast, disruption of the TPM1 TM gene
leads to disappearance of actin cables supporting cytoskeletal
architecture; mutation of the cdc 8 TM gene impairs
cytokinesis.18 19 Haploinsufficiency of
TM in Drosophila leads to disruption of myofibrillar thin
filament assembly.14 20 Deficiency of TM in
axolotl results in severe cardiac abnormalities, which include
disorganized myofibrillar structures with an associated lack of
heartbeat.21 In humans, missense mutations in
-TM are associated with FHC.22 The FHC
mutations in
-TM produce detectable changes in the
Ca2+ regulation of the sarcomere, presumably by
alterations in TM-troponin interactions.16 23 On
the basis of the transgenic animal models we have generated, we
speculate that in humans encoding
-TM FHC mutations the total amount
of TM would also remain unchanged. The mutant TM mRNA is translated
less efficiently than wild-type
-TM transcripts, but the mutant
protein that is produced is incorporated into the sarcomere and
disrupts myofiber function. Thus, the results of these studies strongly
indicate that it is unlikely that
-TM mutations associated with
haploinsufficiency lead to cardiac abnormalities, as can occur with
-myosin heavy chain gene ablations.12
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
-TM knockout mice. We acknowledge K. Pieples for data on
-TM
slow skeletal isoform expression. Also, we acknowledge Drs G. Shull, G.
Dean, and especially M. Periasamy for their critical reading of
the manuscript. | Footnotes |
|---|
Received August 21, 1997; accepted December 1, 1997.
| References |
|---|
|
|
|---|
-tropomyosin gene generates a minimum of six different mRNAs
coding for striated, smooth, and nonmuscle isoforms by alternative
splicing. Mol Cell Biol. 1988;8:679694.
-tropomyosin in hearts of
transgenic mice induces changes in thin filament response to
Ca2+ strong cross-bridge binding, and protein
phosphorylation. J Biol Chem. 1996;271:1161111614.
myosin heavy chain gene leads to dosage effects and functional
deficits in the heart. J Clin Invest. 1996;98:19061917.[Medline]
[Order article via Infotrieve]
-Tropomyosin gene
organization. J Biol Chem. 1987;262:47554765.
-actin-deficient mice
by enteric smooth muscle
-actin. Proc Natl Acad Sci
U S A. 1997;94:44064411.
-tropomyosin 175 mutation (D175N) leads
to abnormal cardiac function. Presented at: Keystone Symposia:
Molecular Biology of Muscle Development; Snowmass, CO, April 16,
1997; Abstract 55a.
-Tm show altered myofilament
sensitivity to Ca2+. Biophys J. 1997;72:57a. Abstract.
-Tropomyosin and cardiac
troponin T mutations cause familial hypertrophic
cardiomyopathy: a disease of the sarcomere.
Cell. 1994;77:701712.[Medline]
[Order article via Infotrieve]
-tropomyosin,
asp175asn and glu180gly, on Ca2+ regulation of
thin filament motility. Biochem Biophys Res Commun. 1997;236:760764.[Medline]
[Order article via Infotrieve]
This article has been cited by other articles:
![]() |
J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Schevzov, T. Fath, B. Vrhovski, N. Vlahovich, S. Rajan, J. Hook, J. E. Joya, F. Lemckert, F. Puttur, J. J.-C. Lin, et al. Divergent Regulation of the Sarcomere and the Cytoskeleton J. Biol. Chem., January 4, 2008; 283(1): 275 - 283. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Gunning, G. O'neill, and E. Hardeman Tropomyosin-Based Regulation of the Actin Cytoskeleton in Time and Space Physiol Rev, January 1, 2008; 88(1): 1 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Pasquet, F. Naye, C. Faucheux, O. Bronchain, A. Chesneau, P. Thiebaud, and N. Theze Transcription Enhancer Factor-1-dependent Expression of the {alpha}-Tropomyosin Gene in the Three Muscle Cell Types J. Biol. Chem., November 10, 2006; 281(45): 34406 - 34420. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. V. Manh, M. Mokrane, E. Georgenthum, J. Flavigny, L. Carrier, M. Semeriva, M. Piovant, and L. Roder Expression of cardiac myosin-binding protein-C (cMyBP-C) in Drosophila as a model for the study of human cardiomyopathies Hum. Mol. Genet., January 1, 2005; 14(1): 7 - 17. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wernicke, C. Thiel, C. M. Duja-Isac, K. V. Essin, M. Spindler, D. J. R. Nunez, R. Plehm, N. Wessel, A. Hammes, R.-J. Edwards, et al. {alpha}-Tropomyosin mutations Asp175Asn and Glu180Gly affect cardiac function in transgenic rats in different ways Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2004; 287(3): R685 - R695. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Ellis, C. W. J. Smith, and P. Kemp Regulated Tissue-specific Alternative Splicing of Enhanced Green Fluorescent Protein Transgenes Conferred by {alpha}-Tropomyosin Regulatory Elements in Transgenic Mice J. Biol. Chem., August 27, 2004; 279(35): 36660 - 36669. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ono and S. Ono Tropomyosin and Troponin Are Required for Ovarian Contraction in the Caenorhabditis elegans Reproductive System Mol. Biol. Cell, June 1, 2004; 15(6): 2782 - 2793. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hook, F. Lemckert, H. Qin, G. Schevzov, and P. Gunning Gamma Tropomyosin Gene Products Are Required for Embryonic Development Mol. Cell. Biol., March 15, 2004; 24(6): 2318 - 2323. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Marston and C. S. Redwood Modulation of Thin Filament Activation by Breakdown or Isoform Switching of Thin Filament Proteins: Physiological and Pathological Implications Circ. Res., December 12, 2003; 93(12): 1170 - 1178. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Fritz-Six, P. R. Cox, R. S. Fischer, B. Xu, C. C. Gregorio, H. Y. Zoghbi, and V. M. Fowler Aberrant myofibril assembly in tropomodulin1 null mice leads to aborted heart development and embryonic lethality J. Cell Biol., December 8, 2003; 163(5): 1033 - 1044. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Mudry, C. N. Perry, M. Richards, V. M. Fowler, and C. C. Gregorio The interaction of tropomodulin with tropomyosin stabilizes thin filaments in cardiac myocytes J. Cell Biol., September 15, 2003; 162(6): 1057 - 1068. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Brittsan, K. S. Ginsburg, G. Chu, A. Yatani, B. M. Wolska, A. G. Schmidt, M. Asahi, D. H. MacLennan, D. M. Bers, and E. G. Kranias Chronic SR Ca2+-ATPase Inhibition Causes Adaptive Changes in Cellular Ca2+ Transport Circ. Res., April 18, 2003; 92(7): 769 - 776. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ono and K. Ono Tropomyosin inhibits ADF/cofilin-dependent actin filament dynamics J. Cell Biol., March 18, 2002; 156(6): 1065 - 1076. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Prabhakar, G. P. Boivin, B. Hoit, and D. F. Wieczorek Rescue of High Expression beta -Tropomyosin Transgenic Mice by 5-Propyl-2-thiouracil. REGULATING THE alpha -MYOSIN HEAVY CHAIN PROMOTER J. Biol. Chem., October 8, 1999; 274(41): 29558 - 29563. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Muthuchamy, K. Pieples, P. Rethinasamy, B. Hoit, I. L. Grupp, G. P. Boivin, B. Wolska, C. Evans, R. J. Solaro, and D. F. Wieczorek Mouse Model of a Familial Hypertrophic Cardiomyopathy Mutation in {alpha}-Tropomyosin Manifests Cardiac Dysfunction Circ. Res., July 9, 1999; 85(1): 47 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Michele, F. P. Albayya, and J. M. Metzger Thin Filament Protein Dynamics in Fully Differentiated Adult Cardiac Myocytes: Toward A Model of Sarcomere Maintenance J. Cell Biol., June 28, 1999; 145(7): 1483 - 1495. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Minamisawa, Y. Gu, J. Ross Jr., K. R. Chien, and J. Chen A Post-transcriptional Compensatory Pathway in Heterozygous Ventricular Myosin Light Chain 2-Deficient Mice Results in Lack of Gene Dosage Effect during Normal Cardiac Growth or Hypertrophy J. Biol. Chem., April 9, 1999; 274(15): 10066 - 10070. [Abstract] [Full Text] [PDF] |
||||